Neovasc Announces First Quarter 2021 Financial Results
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 6, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today reported financial results for the first quarter ended March 31, 2021.First Quarter HighlightsGenerated revenue of $451,794 in the quarter as Neovasc Reducer™ implants rebounded after being suppressed for much of 2020 due to the COVID-19 pandemic. Continued to advance our program to expand reimbursement for Reducer in the EU and the US, and...
2021-05-06 4:05 PM EDT
Neovasc Provides Reducer Reimbursement Progress Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 28, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ ("Reducer").Expanding reimbursement for the Reducer is a key component of Neovasc's strategy to create shareholder value. In many markets around the world, access to reimbursement is a critical step towards driving market...
2021-04-28 9:05 AM EDT
Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 27, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.Interested parties may access the conference call by dialing (866) 269-4262 or (856) 344-9208...
2021-04-27 9:05 AM EDT
Neovasc Comments on EuroIntervention Article
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 19, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal EuroIntervention has published an article entitled, "Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina." The article, authored by Carlo Zivelonghi, M.D., Antwerp Cardiovascular Center, Antwerp, Belgium, describes objective...
2021-04-19 9:05 AM EDT
Neovasc Provides Tiara TA Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 16, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today announced that the Tiara Transapical system ("Tiara TA") will be unable to receive a European CE mark under the current Medical Device Directive regulations ("MDD") ending on May 26, 2021. The Company is collaborating with its European Notified Body (the "Notified Body") on potential next steps. Neovasc has been working with its Notified...
2021-04-16 9:27 AM EDT
Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 11, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter HighlightsGenerated revenue of $514,000 in the quarter and $1.97 million for the full year as Reducer implants rebounded after declining due to the COVID-19 pandemic.In December, announced the completion of the first Neovasc Reducer™...
2021-03-11 4:05 PM EST
Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 4, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.Interested parties may access the conference call by dialing (877)...
2021-03-04 9:00 AM EST
Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 3, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021. A recorded presentation by Bill Little, Neovasc's Chief Operating Officer, will be available on the Conference website starting at 7:00 am EST on March 9. Company management will also be scheduling...
2021-03-03 4:30 PM EST
Neovasc Comments on Clinical Cardiology Journal Publication
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 2, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal Clinical Cardiology has published an article entitled, "Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study."The article, authored by Maayan Konigstein, M.D., Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Israel describes the long-term...
2021-03-02 9:00 AM EST
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules").Neovasc received a letter from the Nasdaq in...
2021-02-24 4:05 PM EST
Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference
Vancouver, British Columbia--(Newsfile Corp. - February 17, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference that is scheduled to take place from February 24 to 26, 2021. Fred Colen, Neovasc's President and Chief Executive Officer, will present on Friday, February 26, 2021 at 1:00 pm EST.A link to the live webcast of the presentation will be available online from the...
2021-02-17 9:00 AM EST
Neovasc Announces Closing of US$72 Million Registered Direct Offering of Common Shares Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - February 12, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) announced today that it has closed its previously announced sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for aggregate gross proceeds to the Company of approximately US$72 million,...
2021-02-12 3:53 PM EST
Neovasc Announces US$72 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for aggregate...
2021-02-10 7:38 AM EST
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 9, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.Currently, the Company is still not in...
2021-02-09 9:00 AM EST
Neovasc Comments on Journal of the American Heart Association Publication
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 5, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Journal of the American Heart Association has published an article entitled, "Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina". The prestigious journal is the official publication of the American Heart Association, and the article offers important insights into the burden of...
2021-02-05 9:00 AM EST
Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 2, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the German Institute for the Hospital Remuneration System("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once again for 2021. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines,...
2021-02-02 9:32 AM EST
American Medical Association Issues New CPT Code for Neovasc Reducer Procedure
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 29, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Category III Code for transcatheter implantation of a coronary sinus reduction device. The code is effective July 1, 2021.The AMA is responsible for managing the CPT coding system that the Centers for Medicare and Medicaid...
2021-01-29 8:00 AM EST
Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy
Bristish Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 19, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that the Neovasc Reducer™ ("Reducer") was prominently featured in three peer reviewed European Journals. "Management of refractory angina: an update(1)" was published in the European Heart Journal. This leading publication came to the conclusion, "At present, accumulating evidence supports the clinical benefit of the Reducer...
2021-01-19 8:33 AM EST
Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received a "not-approvable" letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer™ (Reducer).Fred Colen, Neovasc CEO, said, "While we are disappointed in FDA's decision, the letter was not unexpected, given the outcome of the Panel meeting." He continued, "Millions of patients suffer...
2021-01-15 5:14 PM EST
Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 4, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021. Neovasc President and Chief Executive Officer Fred Colen, Chief Operating Officer Bill Little, and Chief Financial Officer Chris Clark will be available for one-on-one investor meetings during the event; meetings may be requested through H.C....
2021-01-04 4:05 PM EST